TRANSVERSE MYELITIS IN SYSTEMIC LUPUS ERYTHEMATOSUS; CASE REPORT
PDF
Cite
Share
Request
Case Report and Literature Review
P: 89-91
June 2024

TRANSVERSE MYELITIS IN SYSTEMIC LUPUS ERYTHEMATOSUS; CASE REPORT

Rheumatol Q 2024;2(2):89-91
1. University of Health Sciences Turkey Beyhekim Training and Research Hospital, Clinic of Rheumatology, Konya, Turkey
2. Necmettin Erbakan University Meram Faculty of Medicine Department of Rheumatology, Konya, Turkey
No information available.
No information available
Received Date: 14.11.2023
Accepted Date: 28.12.2023
PDF
Cite
Share
Request

Abstract

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can affect any organ, including the nervous system. Estimates of the incidence and prevalence of neurologic and psychiatric symptoms in SLE patients vary widely, largely due to heterogeneity in definition and methodology. In total, studies report that approximately one-third to one-half of SLE patients have neurologic or neuropsychiatric symptomatology. For many of the phenotypic manifestations of neuropsychiatric SLE, no biomarker or diagnostic test is specific enough to link the neurological diagnosis to SLE. Myelitis in SLE is a rare but morbid condition that occurs in approximately 1 to 2 percent of SLE patients in some cohorts. In this case report, we aimed to present the diagnosis and treatment of transverse myelitis in a patient who presented with acute flaccid paralysis in the lower extremity.

Keywords: Systemic lupus erythematosus, neuropsychiatric involvement, myelitis

INTRODUCTION

Systemic lupus erythematosus (SLE) is a chronic autoimmune connective tissue disease of unknown etiology that is common in women of childbearing age and can affect almost every organ of the body. Acute transverse myelitis (TM) is a rare but serious acquired neuro-immune spinal cord disorder that may present with sudden loss of muscle strength, sensory changes and bowel or bladder dysfunction. It is observed in 1-2% of SLE patients (1-5). Currently, only a very limited number of cases of TM-associated SLE have been reported. A 2010 epidemiologic study showed that the incidence of TM at 3.6 per 100.000 (6). The pathogenesis is largely unknown and the clinical presentation is variable. There are still no established guidelines for diagnosis, management or monitoring and the role of autoantibodies is controversial. Lesions often involve the thoracic medulla and the primary clinical manifestations include paralysis of the limbs below the lesion site, conduction bundle sensory disturbance and dysphoria, and voiding dysfunction (7)  In this case report, we aimed to present the diagnosis and treatment of TM in a patient who presented with acute flaccid paralysis in the lower extremity.

CASE REPORT

A 27-year-old woman with SLE since the age of 20 years, married, with one child, presented to the emergency department with the complaint of loss of strength in the legs. Two days ago, antibiotics were started by the dentist due to toothache and the patient discontinued the medication. Sudden loss of strength in the lower extremities develops after a stress. On examination, finger flexion muscle was 3/5 in both hands. Upper extremity deep tondon reflexes were normal and no pathological reflex was found. Deep tendon reflexes of the patient with flaccid paralysis in the lower extremity could not be obtained, but no pathological reflex was detected. The patient was taken over by neurology. No abnormality was detected on brain imaging and increased intensity at the C5-T2 level on spinal magnetic resonance imaging (MRI) was interpreted in favour of myelopathy (Figure 1). No abnormality was found in cerebrospinal fluid (CSF) analysis. Laboratory tests revealed white blood count: 7.6/mm3 (NE# 11.5/mm3), hemoglobin 11.4 g/dL, normal platelet count, erythrocyte sedimentation rate 40 mm/hour, C-reactive protein level of 53 mg/dL, anti nuclear antibody homogenous 3+ and anti-ribosomal P and anti-histone antibody positivity in the extractable nuclear antigen profile. Anti-neutrophil cytoplasmic anti-body immune florescence, antiPR3, anti-myeloperoxidase Enzyme-Linked Immunosorbent Assay test were negative, anti-dsDNA was positive and C3-C4 was low. In addition, neuromyelitis optica IgG was negative. Liver and renal function tests were within normal limits. The patient was treated with 1 g/day methylprednisolone (MP) and 120 g intravenous immunoglobulin (IVIG) followed by 1000 mg cyclophosphamide (CTX). Plasma Exchange (PLEX) was performed in the patient in whom no significant clinical change was observed. The patient is in the 3rd month of treatment and started to walk with person-assisted walking with rehabilitation.

CONCLUSION

TM is one of the neuropsychiatric involvements associated with SLE (NPSLE). Patients present with acute to subacute paraparesis or quadriparesis, usually bilateral but not always symmetrical; sensory impairment, which may be localised at the level of spinal sensation; and/or impaired bowel or bladder function. In SLE-associated myelitis, MRI often shows T2 hyperintensity in the affected area of the spinal cord. CSF examination may show a pleocytosis, usually lymphocytic. The outcome of CSF in SLE patients with TM is currently controversial because some studies have shown that CSF is normal in SLE patients with TM. Treatment is started with pulse glucocorticoids. CTX and Rituximab (RTX) are first-line agents in TM. Plasmapheresis can be applied simultaneously. CTX treatment is usually continued for three to six months and then switched to a less toxic agent for maintenance therapy such as mycophenolate, azathioprine or rituximab to control SLE disease activity and reduce the risk of relapse (8-10). Early aggressive treatment, especially for initially severe myelitis, may be crucial to achieve a favorable outcome. Recently, MP pulse therapy in combination with CTX has been recommended for NPSLE. RTX, a promising modality, has also been reported to be effective in the treatment of new-onset SLE-associated TM (11) and the positive benefits of PLEX and IVIG in patients with refractory NPSLE have also been recognized (12). In recent clinical trials, anti-interleukin 6 agents (tocilizumab and satralizumab) have also shown efficacy in preventing TM attacks (13). Only 40-50% of NPSLE occurs in the presence of active disease in other organ systems of SLE (14). SLE-associated TM can also develop without active disease in other organ systems (15). Therefore, disease activity factors may not predict a worse prognosis. A literature review has shown that recurrence of myelitis will occur several months after the first event, and recurrence occurs at least once in 21-55% of patients (16). Due to its poor prognosis, SLE-TM brings emotional stress and economic burden to the patient’s family and society. In the future, there is a need for controlled clinical treatment studies, which can especially inspire the management of this disease.

Ethics

Informed Consent: Informed patient consent form was prepared.

Authorship Contributions

Concept: S.P., A.K., Design: S.P., A.K., Data Collection or Processing: S.P., A.K., Analysis or Interpretation: S.P., A.K., Literature Search: S.P., A.K., Writing: S.P., A.K.

Conflict of Interest: One author of this article, Adem Küçük, is a member of the editorial board of the Rheumatology Quarterly. However, he did not take part in any stage of the editorial decision of the manuscript. The editors who evaluated this manuscript are from different institutions. The other authors declared no conflict of interest.

Financial Disclosure: The authors declared that this study received no financial support.

References

1
Hanly JG, Urowitz MB, Su L, et al. Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. Ann Rheum Dis. 2010;69:529-35.
2
Ahn G, Kim D, Won S, et al. Prevalence, risk factors, and impact on mortality of neuropsychiatric lupus: a prospective, single-center study. Lupu. 2018;27:1338-47.
3
Muhammed H, Goyal M, Lal V, et al. Neuropsychiatric manifestations are not uncommon in Indian lupus patients and negatively affect quality of life. Lupus. 2018;27:688-93.
4
El Hadidi KT, Medhat BM, Abdel Baki NM, et al. Characteristics of systemic lupus erythematosus in a sample of the Egyptian population: a retrospective cohort of 1109 patients from a single center. Lupus. 2018;27:1030-8.
5
Hanly JG, Urowitz MB, Gordon C, et al. Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. Ann Rheum Dis. 2020;79:356-62.
6
Klein N, Ray P, Carpenter D, et al. Rates of autoimmune diseases in Kaiser Permanente for use in vaccine adverse event safety studies. Vaccine. 2010;28:1062-8.
7
Jacob A, Weinshenker BG. An approach to the diagnosis of acute transverse myelitis. Semin Neurol. 2008;28:105-20.
8
Tomietto P, D’Agostini S, Annese V, et al. Mycophenolate mofetil and intravenous dexamethasone in the treatment of persistent lupus myelitis. J Rheumatol. 2007;34:588-91.
9
Armstrong D, McCarron M, Wright G. SLE-associated transverse myelitis successfully treated with Rituximab (anti-CD20 monoclonal antibody). Rheumatol Int. 2006;26::771-2.
10
Mehmood T, Munir I, Abduraimova M, et al. Longitudinally extensive transverse myelitis associated with systemic lupus erythematosus: a case report and literature review. Am J Med Case Rep. 2019;7:244-9.
11
Ye Y, Qian J, Gu Y, et al. Rituximab in the treatment of severe lupus myelopathy.Clin Rheumatol. 2011;30:981-6.
12
Neuwelt C. The role of plasmapheresis in the treatment of severe central nervous system neuropsychiatric systemic lupus erythematosus.Ther Apher Dial. 2003;7:173-82.
13
Bonnan M, Valentino R, Debeugny S, et al. Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders. J Neurol Neurosurg Psychiatry. 2018;89:346-51.
14
Jordan KM, Arden NK, Doherty M, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003;62:1145-55.
15
Espinosa G, Mendizábal A, Mínguez S, et al. Transverse myelitis affecting more than 4 spinal segments associated with systemic lupus erythematosus: clinical, immunological, and radiological characteristics of 22 patients. Semin Arthritis Rheum. 2010;39:246-56.
16
Schulz S, Shenin M, Mehta A. et al. Initial presentation of acute transverse myelitis in systemic lupus erythematosus: demographics, diagnosis, management and comparison to idiopathic cases.Rheumatol Int. 2012;32:2623-7.
2024 ©️ Galenos Publishing House